| 1 |
Pang XX, Xie L, Yao WJ, Liu XX, Pan B, Chen N. Advancements of molecular imaging and radiomics in pancreatic carcinoma. World J Radiol 2023; 15(1): 10-19 [DOI: 10.4329/wjr.v15.i1.10] [Reference Citation Analysis]
|
| 2 |
Pellegrino F, Granata V, Fusco R, Grassi F, Tafuto S, Perrucci L, Tralli G, Scaglione M. Diagnostic Management of Gastroenteropancreatic Neuroendocrine Neoplasms: Technique Optimization and Tips and Tricks for Radiologists. Tomography 2023;9:217-46. [PMID: 36828370 DOI: 10.3390/tomography9010018] [Reference Citation Analysis]
|
| 3 |
Paik WH, Lee KJ. Management of Small Nonfunctioning Pancreatic Neuroendocrine Neoplasms: Current Opinion and Controversies. J Clin Med 2022;12. [PMID: 36615051 DOI: 10.3390/jcm12010251] [Reference Citation Analysis]
|
| 4 |
Pomposelli E, Rossi M, Gallo M. Ruolo delle indagini diagnostiche di medicina nucleare nelle neoplasie neuroendocrine. L'Endocrinologo 2022;23:32-34. [DOI: 10.1007/s40619-022-01097-2] [Reference Citation Analysis]
|
| 5 |
Gamal GH. The utility of 18F-FDG PET/CT in the diagnosis, staging of non-functioning pancreatic neuroendocrine tumors. Egypt J Radiol Nucl Med 2021;52:234. [DOI: 10.1186/s43055-021-00617-8] [Reference Citation Analysis]
|
| 6 |
Opalińska M, Sowa-staszczak A, Al Maraih I, Gilis-januszewska A, Hubalewska-dydejczyk A. Peptide receptor radionuclide therapy as a tool for the treatment of severe hypoglycemia in patients with primary inoperable insulinoma. Bio-Algorithms and Med-Systems 2022;17:221-6. [DOI: 10.1515/bams-2021-0138] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 7 |
Segaran N, Devine C, Wang M, Ganeshan D. Current update on imaging for pancreatic neuroendocrine neoplasms. World J Clin Oncol 2021; 12(10): 897-911 [PMID: 34733612 DOI: 10.5306/wjco.v12.i10.897] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 8 |
Popa O, Taban SM, Pantea S, Plopeanu AD, Barna RA, Cornianu M, Pascu AA, Dema ALC. The new WHO classification of gastrointestinal neuroendocrine tumors and immunohistochemical expression of somatostatin receptor 2 and 5. Exp Ther Med 2021;22:1179. [PMID: 34475969 DOI: 10.3892/etm.2021.10613] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
|
